Skip to main content

Articles

Perspectives
Advancing Anticoagulation Safety: Focus on Factor Xa Reversal
Read More
Original Research
A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making
Madison M. Wempe, BS; Mark D. Stewart, PhD; Daniel Glass, PhD; Laura Lasiter, PhD; Diana Merino Vega, PhD; Nisha Ramamurthy; Jeff Allen, PhD; Ellen V. Sigal, PhD
Stakeholder Perspective
Navigating the Complex World of Diagnostic Tests and Their Role in Clinical Decision-Making
James T. Kenney, RPh, MBA
Read More
Practice Management
Return to Business During a Pandemic: Market Collaboration and Health Benefit Trends
F. Randy Vogenberg, PhD, RPh
Read More
Perspectives
Healthcare Disrupters
David B. Nash, MD, MBA
Read More
Practice Management
Preparing for Healthcare After COVID-19: New Challenges Facing Payers
Wayne Kuznar
Read More
Original Research, Practice Management
Budget Impact Analysis of a Home-Based Nutrition Program for Adults at Risk for Malnutrition
Suela Sulo, PhD, MSc; David Lanctin, MPH; Josh Feldstein, BA; Bjoern Schwander, MA, RN; Jamie Partridge, PhD, MBA; Wendy Landow, MPH; York F. Zöllner, MSc
Read More
FDA Approvals
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
Read More
FDA Approvals, Lung Cancer, Oncology
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
FDA Approvals, Lung Cancer, Oncology
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
FDA Approvals, Lung Cancer, Oncology
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Read More
Page 34 of 244
Results 331 - 340 of 2434